Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 326 | 47 | 274 |
| Samples | 177 | 32 | 142 |
| Peptides | 149 | 23 | 125 |
Function
STRADB · STE20 related adaptor beta
This gene encodes a protein that belongs to the serine/threonine protein kinase STE20 subfamily. One of the active site residues in the protein kinase domain of this protein is altered, and it is thus a pseudokinase. This protein is a component of a complex involved in the activation of serine/threonine kinase 11, a master kinase that regulates cell polarity and energy-generating metabolism. This complex regulates the relocation of this kinase from the nucleus to the cytoplasm, and it is essential for G1 cell cycle arrest mediated by this kinase. The protein encoded by this gene can also interact with the X chromosome-linked inhibitor of apoptosis protein, and this interaction enhances the anti-apoptotic activity of this protein via the JNK1 signal transduction pathway. Two pseudogenes, located on chromosomes 1 and 7, have been found for this gene. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2011].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 139 amino-acid changes on canonical ENST00000194530 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STRADB · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STRADB – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 11/612 2% |
| Melanoma | 7/210 3% | 18/1899 1% |
| Colorectal Carcinoma | 5/143 4% | 24/3239 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 10/1592 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 0/94 0% | 8/1515 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Head and Neck Carcinoma | 1/85 1% | 6/1574 0% |
| Neuroendocrine Tumour | 2/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Ovarian Carcinoma | 4/109 4% | 0/998 0% |
| Hepatocellular Carcinoma | 2/46 4% | 6/2210 0% |
| Prostate Carcinoma | 0/13 0% | 7/2105 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 3/1390 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Kidney Carcinoma | 1/85 1% | 2/1862 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Other Sarcomas | 0/69 0% | 1/699 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 3/2550 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
Mutation Distribution
Where STRADB is mutated · all tissues, split by cell line vs tissue
How many mutations in STRADB were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 326 mutations in STRADB
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|